Cue Biopharma Q2 revenue rises to $7.9 million; net loss widens to $153.1 million
Cue Biopharma reported a second quarter 2026 revenue increase to $7.9 million from $3.0 million, but its net loss grew to $153.1 million from $8.5 million. The company attributed the larger loss mainly to one-time non-cash losses and expenses tied to its CUE-221 license agreement with Ascendant, and it had $17.4 million in cash at June 30, 2026 before a $50 million private placement completed after quarter end.
Key points
- Second quarter revenue was $7.9 million, versus $3.0 million a year earlier, driven by a preclinical milestone under the Boehringer Ingelheim collaboration.
- Net loss was $153.1 million, or $24.14 per share, versus $8.5 million, or $2.67 per share, in the second quarter of 2025.
- Cash and cash equivalents were $17.4 million at June 30, 2026; a $50 million private placement was completed after quarter end.
- Phase 2 data readout for CUE-221 in Chronic Spontaneous Urticaria is anticipated by the end of the third quarter of 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.